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Background: Non-medical prescription opioid use (NMPOU) and prescription opioid (PO) related harms have
become major substance use and public health problems in North America, the region with the world’s highest PO
use levels. In Ontario, Canada’s most populous province, NMPOU rates, PO-related treatment admissions and
accidental mortality have risen sharply in recent years. A series of recent policy interventions from governmental
and non-governmental entities to stem PO-related problems have been implemented since 2010.
Findings: We compared the prevalence of NMPOU in the Ontario general adult population (18 years+) in 2010 and
2011 based on data from the ‘Centre for Addiction and Mental Health (CAMH) Monitor’ (CM), a long-standing
annual telephone interview-based representative population survey of substance use and health indicators. While
‘any PO use’ (in past year) changed non-significantly from 26.6% to 23.9% (Chi2 = 2.511; df = 1; p = 0.113), NMPOU
decreased significantly from 7.7% to 4.0% (Chi2 = 14.786; df = 1; p < 0.001) between 2010 and 2011. Over-time
changes varied by age group but not by sex.
Conclusions: The observed substantial decrease in NMPOU in the Ontario adult population could be related to
recent policy interventions, alongside extensive media reporting, focusing on NMPOU and PO-related harms, and
may mean that these interventions have shown initial effects. However, other casual factors could have been
involved. Thus, it is necessary to systematically examine whether the observed changes will be sustained, and
whether other key PO-related harm indicators (e.g., treatment admissions, accidental mortality) change
correspondingly in order to more systematically assess the impact of the policy measures.
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CanadaBackground
Since about 2000, non-medical use and harms (e.g.,
morbidity, mortality) related to prescription opioids (POs)
have emerged as a major substance use and public health
problem in North America, including Canada [1,2]. While
key facets of this very problem are solidly documented in
the United States (US), the only country in the world with
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reproduction in any medium, provided the orDDD) per capita than Canada, relevant indicator data for
Canada have been available only selectively, in part due to
inadequate monitoring systems [1,3,4].
The most comprehensive Canadian data on NMPOU
and PO-related harms come from Ontario, its most
populous province. There are two reasons for this: overall
PO consumption rates (a known determinant of levels of
PO-related harms) are higher in Ontario than in most other
provinces, and it has the most comprehensive monitoring
data available [5,6]. Specifically, recent Ontario data have
indicated high levels of non-medical prescription opioid use
(NMPOU) in general adult (5.9%; 2010/11) and secondary
student (15.5%; 2011), as well as key marginalized (e.g.,
aboriginal on reserves, street drug users) populations
[1,7,8]. Furthermore, there have been substantive increasesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increases in PO-related accidental mortality since about
2000 [1,2,9]. In addition, extensive variations of PO pre-
scribing, including possible over-prescribing, associated
with elevated morbidity and mortality risks have been
documented in the Ontario population [10,11].
While Canada, unlike countries like the US or Australia,
yet remains without a national strategy targeting the
problem of NMPOU and PO-related harms, various
governmental and non-governmental entities in Ontario
have implemented a number of large-scale interventions
aiming to reduce these problem phenomena in the past
couple of years. For example, in 2010, the Ontario College
of Physicians and Surgeons (CPSO) issued a report con-
taining numerous recommendations for improved regula-
tory control, clinical practice guidelines, and interventions
related to POs with the aim of reducing the “opioid
public health crisis” in Ontario [12]. In November 2010,
the Ontario government passed the ‘Narcotics Safety
and Awareness Act’ (NSAA) as the legal foundation of
its new provincial ‘Narcotics Strategy’ launched in 2011
[13]. A core feature of the NSAA was the implementation
of a prescription monitoring program (PMP) centrally col-
lecting information on POs dispensed by prescribers and
patients [13]. PMPs have been in place in most US states
and Canadian provinces (but not Ontario) and are asso-
ciated with reduced PO dispensing levels, albeit their
effects on PO abuse or harms are not clearly evidenced
[14,15]. In early 2012, the province delisted ‘Oxycontin’
(oxycodone) – a potent PO substance associated with an
extensive share of NMPOU and PO-deaths—which
accounted for 25% (in Defined Daily Doses per popula-
tion) of PO dispensing in 2010 in Ontario [5] from the
province’s formulary, triggering a substantive reduction of
its clinical use and availability [16]. These initiatives have
been accompanied by extensive media reporting on the
extent of NMPOU and PO-related harms effects on
individual and public health [17,18].
The above interventions mostly occurred on an ad-
hoc basis, and commentators have emphasized the need
for systematic evaluations of their effects on reducing
NMPOU and harms in Ontario, in the interest of
science, evidence-based policy and public health [16,19].
Important markers for such evaluative efforts are indi-
cators of both any PO use and NMPOU among adults.
These specific indicators are assessed for Ontario by the
‘Centre for Addiction and Mental Health (CAMH)
Monitor’ (CM), a long-standing survey on substance use
and health indicators of the Ontario general adult
population.
Methods and findings
Relevant annual cycles of the CM were based on tele-
phone interviews with randomly selected annual samplesof n = 2024 (2010) and n = 1999 (2011; response rate 51%
for both years) adults ages 18 and older, representative
of the Ontario general adult population. Specifically,
‘any PO use’ in the past year was assessed by the com-
bined results of the two questions: “In the past 12
months how many times, if at all, have you used any
pain relievers (such as Percocet, Percodan, Tylenol #3,
Demerol, OxyContin, codeine) with a prescription or
because a doctor told you to take them?” and “In the last
12 months, if at all, how often did you use pain relievers
without a prescription or without a doctor telling you to
take them?”; NMPOU was assessed by the second question
item only [for further CM methods details, see [20]].
While ‘any PO use’ in the past year changed non-
significantly (26.6% and 23.9%; Chi2 =2.51; df = 1; p = 0.113;
all comparisons were conducted by Rao-Scott adjusted
Chi2 test with complex survey design weighting), the
overall rate of NMPOU decreased significantly from 7.7%
to 4.0% (Chi2 =14.79; df = 1; p < 0.001) among Ontario
adults from 2010 to 2011. Examining the changes by
subgroups, there was a significant interaction of survey
year with age (adjusted Wald test, F (2, 3907) = 3.62;
p = 0.027): reductions occurred among age groups 55+
years (7.6% to 2.1%; Chi2 = 30.41; df = 1; p < 0.001) and
30 – 54 years (8.1% to 3.6%; Chi2 = 9.98; df = 1; p = 0.002)
but not among ages 18 – 29 years (7.0% to 7.0%; Chi2 =
0.00; df = 1; p = 0.987). With respect to sex, the interaction
was only marginally significant at the 7% level (adjusted
Wald test, F (1, 3996) = 3.45; p = 0.063), indicating that
these data offered no evidence that the reductions in
NMPOU were more pronounced in women than in men.
Conclusions
One possible explanation for the observed substantial
(almost 50%) recent decrease in NMPOU among Ontario
adults could be that recent policy measures, combined
with extensive media coverage and evolving social debate
focusing on PO abuse and related harms in Ontario,
may have had some initial effects. However, there is no
empirical evidence for such causal influence at present
which would, for example, require time-series analyses
of relevant indicators if available. Alternatively, factors
like ecological or natural changes in general awareness
about NMPOU, PO-related drug use behaviors or avail-
ability could have contributed to the observed NMPOU
reductions. The demonstrated sizeable drop in NMPOU
among Ontario adults mirrors recent developments in
the US. There, NMPOU has declined in the general
adult population as measured by the National Survey of
Drug Use and Health (NSDUH); specifically, NMPOU
(in past year) among adults 18+ years has declined
significantly from 4.7% (2010) to 4.2% (2011; p < 0.01)
[21]. The parallel reductions in NMPOU in the US
might suggest natural or more universal declines in
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targeted interventions and media reporting regarding
NMPOU and PO-related harms that may have influenced
these phenomena.
Notably, the changes in NMPOU observed in Ontario
are markedly uneven by socio-demographic subgroups,
i.e. sex and age. This deviates from previously observed
patterns of a rather even spread of NMPOU across
these socio-demographic groups [7]. Importantly, the
above NMPOU indicators should be examined over a
longer period of time, and other indicators need to be
monitored, in order to assess whether substantive
reductions in NMPOU are sustained, and other PO-
related harms are correspondingly reduced in Ontario. For
example, NMPOU has been reported to be considerably
higher among Ontario secondary students than in
adults, where it is however not evident at this point
whether similar reduction effects are occurring [7,8].
Furthermore, PO-related emergency room episodes,
substance use treatment admissions as well as accidental
poisoning are all essential harm indicators which need to
be assessed in order to determine whether PO-related
burden of disease has actually been reduced [4,22]. In
addition to these, it will be equally important to monitor
pain care quality, and availability, as these could be com-
promised as an unintended consequence of the above
interventions focusing on PO use [23]. While such evalu-
ative future monitoring efforts are reasonably feasible with
existing data in Ontario, the fragmented existence (or
absence) of systematically comparable indicators across
Canada unfortunately hinders important comparative
evaluation efforts [1].
While it is yet uncertain whether the observed reduc-
tions in NMPOU are causally related to the described
recent interventions, and whether other key PO-related
problems in Ontario are characterized by corresponding
decreases, there are examples from other jurisdictions
where such reductions have been observed following
targeted interventions. For example, the recent imple-
mentation of more restrictive PO dosing guidelines has
resulted in substantive reduction of PO-related mortal-
ity in Washington State [24]. The burden of disease
stemming from NMPOU and harms is extensive in
Ontario [25], and it is essential from both science and
policy perspectives to know whether the comprehensive
interventions launched have been effective or not.
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